文献速递艾滋病与性传播感染

卡博特韦在细菌性性传播感染情况下维持保护效力:HPTN 083 的二次分析

Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083.
PubMed 文献 · Clin Infect Dis · 2026-01-01

HPTN 083 二次分析评估长效卡博特韦(CAB-LA)在存在细菌性性传播感染(梅毒、直肠/尿道淋病和衣原体)时是否维持 HIV 预防效力。3859 名参与者中总体性传播感染发生率为 50.7 例/100 人年,伴或不伴性传播感染时 CAB-LA 较 TDF/FTC 的 HIV 风险比分别为 0.37 和 0.31,性传播感染与 HIV 风险比间无显著交互作用(P = .75)。

要点

  • 3859 名参与者中总体性传播感染发生率为 50.7 例/100 人年。
  • 性传播感染发生率在暴露前预防组间无差异。
  • 伴或不伴性传播感染时 CAB-LA 较 TDF/FTC 的 HIV 风险比分别为 0.37 和 0.31,交互作用 P = .75。

核心结论

  • 在性传播感染高发的大型暴露前预防试验中,存在细菌性性传播感染时 CAB-LA 相对 TDF/FTC 维持稳健的保护效力。

研究设计与样本

  • HPTN 083 的二次分析,纳入 3859 名参与者。
  • 计算每 100 人年的性传播感染事件率并按亚组分析。
  • 采用泊松回归模型分析基线因素与性传播感染发病的关联。
  • 采用以性传播感染状态为时变协变量的 Cox 比例风险模型评估性传播感染状态与 CAB-LA 相对 TDF/FTC 疗效的潜在交互作用。

主要发现

  • 3859 名参与者中总体性传播感染发生率为 50.7 例/100 人年。
  • 1562 名(40.5%)参与者被诊断性传播感染,79% 的性传播感染发生在 25% 的参与者中。
  • 性传播感染发生率在暴露前预防组间无差异。
  • 最终多变量模型中,年龄、地区、种族、教育水平、婚姻状况和基线性传播感染与 incident 性传播感染相关(P < .05)。
  • 伴或不伴性传播感染时,CAB-LA 较 TDF/FTC 的 HIV 发病率风险比分别为 0.37 和 0.31,性传播感染与 HIV 发病率风险比间无显著交互作用(P = .75)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sexually transmitted infections (STIs) have been shown to facilitate human immunodeficiency virus (HIV) transmission and acquisition. HPTN 083, a global clinical trial, demonstrated superiority of long-acting cabotegravir (CAB-LA) versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV prevention among transgender women and cisgender men who have sex with men. This analysis assessed whether CAB-LA maintained protective efficacy when bacterial STIs (syphilis, rectal/urethral gonorrhea, and chlamydia) were present. METHODS: STI events per 100 person-years were calculated, including by subgroups (age, race/ethnicity, gender, education, treatment arm, drug use, alcohol use, region/country, condom usage, partner number, marital status, baseline STI). Association between baseline factors and STI incidence was modeled using Poisson regression. Cox proportional hazards modeling with STI status as a time-varying covariate was used to evaluate potential interactions between STI status and the relative efficacy of CAB-LA versus TDF/FTC. FINDINGS: Among 3859 participants, overall STI incidence rate was 50.7 infections/100 person-years. STIs were diagnosed in 1562 (40.5%) participants; 79% of STIs occurred in 25% of the participants. STI incidence was not different by preexposure prophylaxis arm. In the final multivariable model, age, region, race, education level, marital status, and baseline STI were associated with incident STI (P < .05). HIV incidence was lower with CAB-LA versus TDF/FTC with or without STIs (hazard ratios 0.37 and 0.31, respectively), with no significant interaction between STIs and the HR for HIV incidence (P = .75). CONCLUSIONS: In a large preexposure prophylaxis trial with high STI incidence, CAB-LA maintained robust protective efficacy relative to TDF/FTC in the setting of bacterial STIs.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Clement ME, Hanscom B, Haines D, et al. Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083. Clin Infect Dis. 2026. PMID: 39579334. doi:10.1093/cid/ciae572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。